| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Healthpeak Properties (NYSE:DOC) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 0 | 2 | 2 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 1 | 0 | 0 |
| 2M Ago | 0 | 0 | 1 | 0 | 0 |
| 3M Ago | 0 | 1 | 0 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $20.25, with a high estimate of $21.00 and a low estimate of $19.00. A 7.95% drop is evident in the current average compared to the previous average price target of $22.00.
A comprehensive examination of how financial experts perceive Healthpeak Properties is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Amanda Sweitzer | Baird | Lowers | Outperform | $21.00 | $22.00 |
| Nicholas Yulico | Scotiabank | Lowers | Sector Perform | $19.00 | $21.00 |
| Connor Siversky | Wells Fargo | Lowers | Equal-Weight | $20.00 | $22.00 |
| Nicholas Yulico | Scotiabank | Lowers | Sector Outperform | $21.00 | $23.00 |
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Healthpeak Properties's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Healthpeak Properties analyst ratings.
Healthpeak owns a diversified healthcare portfolio of approximately 700 in-place properties spread across mainly medical office and life science assets, plus a handful of senior housing, hospital, and skilled nursing/post-acute care assets, as well.
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Decline in Revenue: Over the 3M period, Healthpeak Properties faced challenges, resulting in a decline of approximately -0.17% in revenue growth as of 30 June, 2025. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Real Estate sector.
Net Margin: Healthpeak Properties's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 4.54%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 0.39%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Healthpeak Properties's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.16%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Healthpeak Properties's debt-to-equity ratio is below the industry average at 1.18, reflecting a lower dependency on debt financing and a more conservative financial approach.
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: DOC
